ELAB
Elevai Labs, Inc. Common Stock
NASDAQ: ELAB · HEALTHCARE · BIOTECHNOLOGY
$2.53
-0.39% today
Updated 2026-04-29
Market cap
$11.08M
P/E ratio
—
P/S ratio
18.78x
EPS (TTM)
$-382.61
Dividend yield
—
52W range
$2 – $269
Volume
9.0M
Elevai Labs, Inc. Common Stock (ELAB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $827.00 | $766277.00 | $1.71M | $2.47M | $590084.00 |
| Revenue growth (YoY) | — | — | +92557.4% | +123.5% | +44.1% | -76.1% |
| Cost of revenue | — | $2845.00 | $318968.00 | $578015.00 | $670197.00 | $515273.00 |
| Gross profit | — | $-2018.00 | $447309.00 | $1.13M | $1.80M | $74811.00 |
| Gross margin | — | -244.0% | 58.4% | 66.2% | 72.8% | 12.7% |
| R&D | $118857.00 | $123632.00 | $228747.00 | $426243.00 | $104654.00 | $147010.00 |
| SG&A | $95938.00 | $602729.00 | $1.54M | $3.37M | $563242.00 | $1.42M |
| Operating income | $-221844.00 | $-785060.00 | $-1.79M | $-3.76M | $-1.87M | $-7.38M |
| Operating margin | — | -94928.7% | -233.4% | -219.6% | -75.7% | -1250.1% |
| EBITDA | $-1066.00 | $-782300.00 | $-1.79M | $-4.27M | $-3.20M | $-7.27M |
| EBITDA margin | — | -94594.9% | -233.7% | -249.3% | -129.6% | -1231.4% |
| EBIT | $-222910.00 | $-785057.00 | $-1.80M | $-4.28M | $-3.28M | $-7.38M |
| Interest expense | — | $0.00 | $2629.00 | $19525.00 | $735197.00 | $547128.00 |
| Income tax | $-1066.00 | $3.00 | $-2.00 | $1.00 | — | — |
| Effective tax rate | 0.5% | -0.0% | 0.0% | -0.0% | 0.0% | 0.0% |
| Net income | $-222910.00 | $-784739.00 | $-1.80M | $-4.30M | $-6.25M | $-7.71M |
| Net income growth (YoY) | — | -252.0% | -129.4% | -138.9% | -45.2% | -23.4% |
| Profit margin | — | -94889.8% | -234.9% | -251.2% | -253.1% | -1306.3% |